Last updated: 11/04/2018 10:15:26

A Study of GW856553X For the Treatment of Depression

Request patient level data
GSK study ID
PKI108574
Clinicaltrials.gov ID
NCT00569062
See results summary
EudraCT ID
2006-005578-39
EU CT Number
Not applicable
Trial status
Other
Other
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A randomized, double blind, placebo controlled study to explore the antidepressant properties of P38a Kinase inhibitor GW856553X 15mg compared to PBO in Subjects with Major Depressive Disorder exhibiting symptoms of loss of energy and interest and psychomotor retardation, for a six week treatment period
Trial description: GW856553 is a novel compound, currently in development for the treatment of Major Depressive Disorder (MDD), and other indications. GW856553 inhibits a protein which is responsible for the production of some pro-inflammatory molecules, called cytokines. Increased blood levels of these molecules were seen in populations of MDD patients and this was more apparent in subjects with severe symptoms, psychomotor retardation and loss of energy. Aim of the present study is to assess whether GW856553, by inactivating this protein, is able to suppress the production of the cytokines, and ultimately relieving depression symptoms. In this study GW856553 or placebo is given to MDD patients 7.5md twice daily for 6 weeks.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Change from Randomization at Week 6 in Bech subscale (6-item of 17-item Hamilton depression rating [HAMD-17] scale) score

Timeframe: Day 1 (Randomization, Week 0) and Week 6

Change from Randomization (Week 0) at Week 6 in Inventory for Depressive Symptomatology-Clinician rated (IDS-C) scale total score

Timeframe: Day 1 (Randomization, Week 0) and Week 6

Change from randomization (Week 0) at Week 6 in Quick Inventory of Depressive symptomatology 16 item self report (QIDS-SR16) scale total score

Timeframe: Day 1 (Randomization, Week 0) and Week 6

Change from Randomization (Week 0) at Week 6 in the morning serum levels of the pro-inflammatory biomarkers

Timeframe: Day 1 (Randomization, Week 0) and Week 6

Secondary outcomes:

Number of participants with any Adverse events (AEs), Serious adverse events (SAEs) or Death

Timeframe: Up to Follow-up (Up to 53 days)

Mean Suicidality Tracking Scale (STS) scores over period

Timeframe: Week 0, Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6

Number of participants with abnormal chemistry values

Timeframe: Day 1 (Randomization, Week 0), Week 1, Week 2 and Week 6

Number of participants with abnormal hematology values

Timeframe: Day 1 (Randomization, Week 0), Week 2 and Week 6

Number of participants with abnormal urinalysis results

Timeframe: Up to Follow-up (Up to 53 days)

Number of participants of vital signs outside range of Potential Clinical Importance (PCI)

Timeframe: Day 1 (Randomization, Week 0), Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6

Number of participants of abnormal electrocardiogram (ECG) values

Timeframe: Week 0, Week 2, Week 4 and Week 6

Change from randomization (Week 0) at Week 1, 2, 3, 4 and 5 in Bech subscale (6-item of HAMD-17 scale) score

Timeframe: Day 1 (Randomization, Week 0), Week 1, Week 2, Week 3, Week 4 and Week 5

Change from Randomization (Week 0) at Week 1, 2, 3, 4 and 5 in IDS-C scale total score

Timeframe: Day 1 (Randomization, Week 0), Week 1, Week 2, Week 3, Week 4 and Week 5

Change from randomization (Week 0) at Week 2 and 4 in QIDS-SR16 scale total score

Timeframe: Day 1 (Randomization, Week 0), Week 2 and Week 4

Change from randomization (Week 0) at Week 1, 2, 3, 4, 5 and 6 in HAMD-17 scale total score

Timeframe: Day 1 (Randomization, Week 0), Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6

Percentage of participants with Bech subscale (6-item HAMD-17) score responder and remitter at Week 6

Timeframe: Week 6

Percentage of participants with IDS-C scale total score responder and remitter at Week 6

Timeframe: Week 6

Percentage of participants with QIDS-SR16 scale total score responder and remitter at Week 6

Timeframe: Week 6

Change from Randomization in Psychomotor Retardation subscale of the IDS-C scale over Week 6

Timeframe: Day 1 (Randomization, Week 0), Week 1, Week 2, Week 3, Week 4 , Week 5 and Week 6

Change from Randomization in Psychomotor Retardation subscale of the QIDS-SR16 scale over Week 6

Timeframe: Day 1 (Randomization, Week 0), Week 2, Week 4 and Week 6

Change from Randomization in Psychomotor Retardation-Psychomotor Slowing item 23 of the IDS-C scale over Week 6

Timeframe: Day 1 (Randomization, Week 0), Week 1, Week 2, Week 3, Week 4 , Week 5 and Week 6

Change from Randomization in Psychomotor Retardation-Psychomotor Slowing item 15 of QIDS-SR16 scale over Week 6

Timeframe: Day 1 (Randomization, Week 0), Week 2, Week 4 and Week 6

Functional assessment of Fatigue and Sleepiness over Week 6

Timeframe: Day 1 (Randomization, Week 0) up to Week 6

Change from Randomization in Visual Analogue Scale (VAS) of Fatigue/Tiredness and Sleepiness (at time of cytokine sampling) over Week 6

Timeframe: Day 1 (Randomization, pre-dose, Week 0), Week 0 (2 h and 4 h post-dose), Week 2 (pre-dose, 2 h and 4 h post-dose) and Week 6 (pre-dose, 2 h and 4 h post-dose

Change from Randomization in Fatigue-Energy item 20 of the IDS-C scale over Week 6

Timeframe: Day 1 (Randomization, Week 0), Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6

Change from Randomization in Energy/Fatigue item 14 of the QIDS-SR16 scale over Week 6

Timeframe: Day 1 (Randomization, Week 0), Week 2, Week 4, and Week 6

Change from Randomization in plasma cortisol over Week 6

Timeframe: Day 1 (Randomization, Week 0), Week 0 (2 h and 4 h post-dose), Week 2 (pre-dose, 2 h and 4 h post dose) and Week 6 (pre-dose, 2 h and 4 h post-dose)

Change from Randomization in serum TNFα/IL-10 ratio over Week 6

Timeframe: Day 1 (Randomization, Week 0), Week 0 (2 h and 4 h post-dose), Week 2 (pre-dose, 2 h and 4 h post dose) and Week 6 (pre-dose, 2 h and 4 h post-dose)

Change from Randomization in high sensitivity C-reactive protein (hs-CRP) over Week 6

Timeframe: Day 1 (Randomization, Week 0), Week 2 and Week 6

Change from Randomization in number of leukocytes over Week 6

Timeframe: Day 1 (Randomization, Week 0) Week 1, Week 2, Week 3, Week 4, Week 5 and Week 6

Plasma concentration of GW856553X and GSK198602

Timeframe: Pre-dose and 4 h post-dose at Week 2 and Week 6

Maximum plasma concentration (Cmax) of GW856553X and GSK198602

Timeframe: Pre-dose and 4 h post-dose at Week 2 and Week 6

Median time to Cmax (tmax) and the terminal phase half-life (t1/2)

Timeframe: Pre-dose and 4 h post-dose at Week 2 and Week 6

The area under the plasma concentration-time curve (AUC)

Timeframe: Pre-dose and 4 h post-dose at Week 2 and Week 6

Interventions:
  • Drug: GW856553X
  • Other: Placebo
    • Enrollment:
    29
    Primary completion date:
    2008-25-06
    Observational study model:
    Not applicable
    Time perspective:
    Not applicable
    Clinical publications:
    Not applicable
    Medical condition
    Depressive Disorder, Major
    Product
    losmapimod
    Collaborators
    Not applicable
    Study date(s)
    September 2007 to June 2008
    Type
    Interventional
    Phase
    2

    Participation criteria

    Sex
    Female & Male
    Age
    18 - 60 years
    Accepts healthy volunteers
    Yes
    • Male or female = 18 years of age and < 60 years,
    • routine laboratory results within normal ranges,
    • The subject has any history of liver disease.
    • The subject has significant cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions that, in the opinion of the investigator and/or GSK medical monitor, places the subject at an unacceptable risk as a participant in this trial.
    Inclusion and exclusion criteria
    Inclusion criteria:
    • Male or female = 18 years of age and < 60 years,
    • routine laboratory results within normal ranges,
    • Body Mass Index within the range 18.5-35.0 kg/m2 inclusive.
    • Subject must have had at least one previous major depressive episode with a diagnosis of MDD in his/her history, and had a successful pharmacological treatment of that episode, and is currently experiencing a recurrence of MDD presently un-medicated.
    • Subjects must met the diagnosis of an episode of Major Depressive Disorder in the past 12 weeks but not greater than 24 months.
    Exclusion criteria:
    • The subject has any history of liver disease.
    • The subject has significant cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal conditions that, in the opinion of the investigator and/or GSK medical monitor, places the subject at an unacceptable risk as a participant in this trial.
    • The subject has a history of autoimmune diseases.
    • The subject has any active infectious diseases, including active tuberculosis or a history of active tuberculosis.
    • The subject has a history of malignancy, except for surgically cured basal cell carcinoma or females with cured cervical carcinoma (> 2 yrs prior).
    • The subject has a history of HIV or other immunosuppressive disease.
    • The subject has uncontrolled diabetes.
    • The subject is pregnant or nursing.
    • Subject has no contact with an adult on a daily basis (i.e., subjects who are not living with at least one other adult or subjects who do not have an adult who contacts them on a daily basis).
    • Subject has initiated psychotherapy within three months prior to the Screening visit, or plans to initiate psychotherapy during the trial.
    • Subject has received electroconvulsive therapy or transcranial magnetic stimulation or vagal nerve stimulation within the six months prior to the Screening.
    • The subject is currently receiving a chronic biological or pharmacologic anti-inflammatory therapy; interferon therapy at any dose or did receive them within 6 months prior randomisation.
    • Subjects who have donated a unit of blood within the previous month or intends to donate in the month after completing the study

    Trial location(s)

    Location
    Status
    Contact us
    Contact us
    Location
    GSK Investigational Site
    Pune, India, 411004
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Manipal,, India, 576 104
    Status
    Terminated/Withdrawn
    Contact us
    Location
    GSK Investigational Site
    Nizhny Novgorod, Russia, 603115
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    St-Petersburg, Russia
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    St.Petersburg, Russia, 193167
    Status
    Study Complete
    Contact us
    Location
    GSK Investigational Site
    Tartu, Estonia, 50417
    Status
    Study Complete
    Contact us
    Showing 1 - 6 of 14 Results

    Study documents

    No study documents available.

    Results overview

    Results posted on ClinicalTrials.gov

    Recruitment status
    Other
    Actual primary completion date
    2008-25-06
    Actual study completion date
    2008-25-06

    Plain language summaries

    Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

    Additional information about the trial

    Participate in clinical trial
    Additional information
    Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
    Click here
    Access to clinical trial data by researchers
    Visit website